期刊
MOLECULAR PSYCHIATRY
卷 26, 期 11, 页码 6992-7005出版社
SPRINGERNATURE
DOI: 10.1038/s41380-019-0453-x
关键词
-
资金
- National Institute of Health [AG055707, AG056689]
VPS35 plays a crucial role in tau metabolism and neuropathology, with its overexpression reducing pathological tau in neuronal cells while genetic silencing leads to accumulation. The availability of active cathepsin D mediates the effect of VPS35 on pathological tau accumulation, making it a potential therapeutic target for human tauopathies.
The vacuolar protein sorting 35 (VPS35) is a major component of the retromer recognition core complex which regulates intracellular protein sorting and trafficking. Deficiency in VPS35 by altering APP/A beta metabolism has been linked to late-onset Alzheimer's disease. Here we report that VPS35 is significantly reduced in Progressive Supra-nuclear Palsy and Picks' disease, two distinct primary tauopathies. In vitro studies show that overexpression of VPS35 leads to a reduction of pathological tau in neuronal cells, whereas genetic silencing of VPS35 results in its accumulation. Mechanistically the availability of active cathepsin D mediates the effect of VPS35 on pathological tau accumulation. Moreover, in a relevant transgenic mouse model of tauopathy, down-regulation of VPS35 results in an exacerbation of motor and learning impairments as well as accumulation of pathological tau and loss of synaptic integrity. Taken together, our data identify VPS35 as a novel critical player in tau metabolism and neuropathology, and a new therapeutic target for human tauopathies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据